NCT05555992

Brief Summary

Background Cardiac Resynchronization Therapy (CRT) is proven to improve survival and heart function of patient with certain electrical conduction abnormality and heart failure. However, in patient with certain electrical conduction abnormality, being nonresponder is observed in up to 40% in patient receiving CRT. Conventionally the surgical approach of CRT is to implant one pacing lead in the right heart and one in the left heart to resynchronize the contraction and the pacing lead in the left heart is usually placed in the posterior or lateral portion of the left heart. However, this single approach may not be optimal, especially for those patients with conduction abnormality known to have no response to CRT. Purpose of the clinical investigation. The purpose of the Electrical Activation Guided CRT for Nonresponders Study is to study the effectiveness of an addition of Hisbundle pacing approach to CRT nonresponder by direct His-bundle pacing to improve the responder rate of nonresponder of conventional CRT and a tailored made approach to CRT procedure by using a noninvasive globally mapping system studying the electrical conduction under different approaches to delivery CRT. The pacing approach that optimally corrects conduction abnormality will be determined before the actual addition of new lead procedure. Conduct of the Investigation This study will include 18 patients already implanted with device delivering conventional CRT that known to have no response to the conventional CRT after 6 months of the CRT therapy from Prince of Wales Hospital, Hong Kong. You will be followed in the device clinic as per usual care after your participation in the study is completed.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
18

participants targeted

Target at below P25 for not_applicable heart-failure

Timeline
Completed

Started Jan 2020

Longer than P75 for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 2, 2020

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

September 15, 2022

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 27, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

September 27, 2022

Status Verified

September 1, 2022

Enrollment Period

3.7 years

First QC Date

September 15, 2022

Last Update Submit

September 22, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Left Ventricle end systolic volume reduction

    The responder rate of greater than 10% of LV end systolic volume reduction measured by echocardiogram.

    6 months

Secondary Outcomes (17)

  • Electrical desynchrony index

    During procedure

  • Hemodynamic response monitoring

    During procedure

  • Procedure duration of different methods of CRT delivery

    During procedure

  • Implantation success rate of different methods of CRT delivery

    During procedure

  • Cine images and chest X ray

    6 months

  • +12 more secondary outcomes

Study Arms (1)

Treatment

EXPERIMENTAL
Device: Electrical Activation Mapping Guided Cardiac resynchronization therapy

Interventions

To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation

Treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (aged 18 or above) of both sexes
  • Ischemic or non-ischemic cause of heart failure
  • QRS duration \> 120 ms, non -LBBB type of conduction disturbance
  • NYHA class III or above
  • Informed consent by the patient
  • Already received stable dose of guideline directed medical therapy for at least 3 months

You may not qualify if:

  • LBBB patients
  • Pregnant women
  • Participation in another study
  • Patient with contraindication to left ventricle catheterization by a retrograde aortic approach

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Chinese University of Hong Kong

Shatin, 999077, Hong Kong

RECRUITING

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Byran Yan

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 15, 2022

First Posted

September 27, 2022

Study Start

January 2, 2020

Primary Completion

August 31, 2023

Study Completion

December 31, 2023

Last Updated

September 27, 2022

Record last verified: 2022-09

Locations